

# Understanding the Enhancing Oncology Model (EOM): Implications for Future Management



Panel

Ray Bailey, RPh, Consultant

Formerly of Florida Cancer Specialists (FCS)



Victoria Nachar, PharmD, BCOP

Hematology Clinical Pharmacist Specialist University of Michigan Rogel Cancer Center



Jay Weaver, PharmD, MPH

Former Chief Pharmacy Officer Blue Cross Blue Shield of Kansas City

## **Background**

On July 1, the Center for Medicare and Medicaid Innovation (CMMI) introduced the EOM, the pilot program that is the successor to the Oncology Care Model (OCM). The EOM is a 5-year voluntary model intended to transform care for cancer patients, reduce spending, and improve the quality of care.<sup>1</sup>

Our panel gathered to share their perspectives on the EOM and some of the opportunities and challenges of the new model.

## **Key Highlights**

- Practices participating in the EOM likely believe they have the infrastructure and resources to be successful, based on their experience with the OCM
- According to CMS, 44 practices have chosen to participate in the EOM compared with 122 practices for the OCM.<sup>2</sup> The panel felt that the downside risk may have been challenging for practices and kept participation lower vs the OCM
- New aspects of the EOM, including the social determinants of health screening, were favorably viewed as potentially improving the quality of care and reducing healthcare disparities
- Concerns were raised about the reduction in MEOS payments and how practices would be able to manage the additional workload required by the EOM and stay financially viable

Abbreviation: MEOS, Monthly Enhanced Oncology Services.

"I think the **EOM is well intended and has the opportunity to improve care that patients with cancer receive,** but I think it will be interesting to see how institutions and programs enact the requirements of the EOM."

#### Quick Facts About the EOM







"I am hopeful—I do think moving more and more to **risk-aligned benefits** across providers and plans is the **place we need to be**. From my seat, I'm looking to see how we can help providers **understand the cost differential of different products** and **different services** so that they can **make good choices**."

- Dr. Jay Weaver

#### **Additional Resources**

CMS.gov. Enhancing Oncology Model. https://innovation.cms.gov/innovation-models/enhancing-oncology-model.

CMS.gov. Strategic direction. https://innovation.cms.gov/about/strategic-direction.

American Society of Clinical Oncology. ASCO Fact Sheet: Enhancing Oncology Care Model (EOM). https://practice.asco.org/sites/default/files/drupalfiles/2022-08/ASCO-EOM-Fact-Sheet.pdf.

References: 1. Centers for Medicare & Medicaid Services. Enhancing Oncology Model. Fact sheet. Published June 27, 2022. Accessed June 8, 2023. https://www.cms.gov/newsroom/fact-sheets/enhancing-oncology-model 2. Caffrey M. Final tally lists 44 practices in EOM, but it's complicated. AJMC e-newsletter. Published July 12, 2023. Accessed September 20, 2023. https://www.ajmc.com/view/final-tally-lists-44-practices-in-eom-but-it-s-complicated 3. Benefits and challenges of the Enhancing Oncology Model. Conference Coverage. J Clin Pathways. Published June 13, 2023. Accessed June 13, 2023. https://www.hmpgloballearningnetwork.com/site/jcp/conference-coverage/benefits-and-challenges-enhancing-oncology-model

Abbreviation: PMPM, per member per month.

Visit **BeOneEngage.com** for additional information and resources.





BeOne Medicines trademark is owned by BeOne Medicines USA Inc. or its affiliates. © BeiGene, Ltd. 2025 All Rights Reserved. 0823-NP-PRC-017 Date of preparation: March 2025